

Lupin invests \$250 M to build new state-of-the-art manufacturing facility in US

09 October 2025 | News

To strengthen the company's position as a global respiratory leader



Global pharmaceutical leader Lupin has announced its plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, US. With a projected cumulative investment of \$250 million, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, including lifesaving albuterol inhalers for children with asthma and service members at home and overseas.

By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen Lupin's position as a global respiratory leader. Locally, this will generate over 200 new long-term, skilled jobs by 2030 in Broward County.

"The expansion of Lupin's footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin's headquarters and our Advanced Inhalation Research Center", said Christoph Funke, Chief Technical Operations Officer, Lupin.

The Coral Springs facility will anchor US production of critical respiratory therapies, diversify the supply chain, and ensure affordable, reliable access—from routine pediatric care to pandemic-scale demand. Lupin has acquired more than 5 acres of land to embark on this expansion of 70,000 square feet.

In recognition of its investment and job creation plans, Lupin will receive tax credits and incentives from the state of Florida. Lupin is partnering with Florida Commerce/Select Florida; City of Coral Springs; Greater Fort Lauderdale Alliance; Broward County Commission, [Workforce/college partner] as part of this strategic project.